Memantine pharmacotherapy: A naturalistic study using a population pharmacokinetic approach

Clinical Pharmacokinetics

Volumn 46, Issue 7, 2007, Pages 599-612

  Kornhuber, Johannes ^a   Kennepohl, Evelin M ^a   Bleich, Stefan ^a   Wiltfang, Jens ^a   Kraus, Thomas ^a   Reulbach, Udo ^a   Meineke, Ingolf ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; MEMANTINE;

ADULT; AGED; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; COMPUTER PROGRAM; CONFUSION; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; FEMALE; HUMAN; KIDNEY TUBULE EXCRETION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SMOKING; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MEMANTINE; MENTAL DISORDERS; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; RESEARCH DESIGN; SOLUTIONS; TABLETS;

EID: 34347377858     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746070-00005     Document Type: Article

References (44)

1. Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43: 91-104
2. Möbius HJ, Stöffler A, Graham SM. Memantine hydrochloride: pharmacological and clinical profile. Drugs Today (Barc) 2004; 40 (8): 685-95
3. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989; 166: 589-90
4. Bormann J. Memantine is a potent blocker of N-methyl-D-Bayesian aspartate (NMDA) receptor channels. Eur J Pharmacol 1989; 166: 591-2
5. Kornhuber J, Bormann J, Hübers M, et al. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 1991; 206: 297-300
6. Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 1995; 195: 137-9
7. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use: Axura. European public assessment report [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/axura/axura.htm [Accessed 2007 May 18]
8. European Medicines Agency (EMEA). Initial scientific discussion for the approval of Axura [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/axura/094802en6.pdf [Accessed 2007 May 18]
9. Freudenthaler S, Görtelmeyer R, Pantev M, et al. Dose-response analysis to support dosage recommendations for memantine. Naunyn-Schmiedebergs Arch Pharmacol 1996; 353 Suppl.: R159
10. Periclou A, Ventura D, Rao N, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006; 79 (1): 134-43
11. Wesemann W, Sontag K-H, Maj J. Zur Pharmakodynamik und Pharmakokinetik des Memantin. Arzneimittelforschung/Drug Res 1983; 33: 1122-34
12. Freudenthaler S, Meineke I, Schreeb KH, et al. Influence of urine pH and urinary flow on the renal excretion of memantine. Br J Clin Pharmacol 1998; 46 (6): 541-6
13. Henkel JG, Hane JT. Structure-anti-Parkinson activity relationships in the aminoadamantanes: influence of bridgehead subin stitution. J Med Chem 1982; 25: 51-6
14. Micuda S, Mundlova L, Anzenbacherova E, et al. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol 2004; 60: 583-9
15. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991; 32: 669-70
16. Beal SL, Sheiner LB. NONMEM users guides, NONMEM Project Group, San Francisco. San Francisco (CA): University of California, 1992
17. FachInfo-Service. Fachinformationsverzeichnis Deutschland, RoteListe Service GmbH - Frankfurt/Main [online]. Available from URL: http://www.fachinfo. de [Accessed 2006 Jan 15]
18. Masereeuw R, Russel FG. Mechanisms and clinical implications of renal drug excretion. Drug Metab Rev 2001; 33 (3-4): 299-351
19. US FDA. Guidance for industry: population pharmacokinetics [online]. Available from URL: http://www.fda.gov/cder/guidance/1852fnl.pdf [Accessed 2007 May 18]
20. Merz + Co. Validation of a GC/MS-method for the quantitative assessment of memantine in human plasma and urine [internal report]. Frankfurt/Main: Merz + Co., 2001
21. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71: 1344-8
22. Hastie T, Tibshirani R. Generalized additive models. Stat Sci 1986; 1: 297-318
23. Hastie T, Tibshirani R. Generalized additive models for medical research. Stat Methods Med Res 1995; 4 (3): 187-96
24. Maitre PO, Buhrer M, Thomson D, et al. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991; 19 (4): 377-84
25. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models I: models for covariate effects. J Pharmacokinet Biopharm 1992; 20 (5): 511-28
26. Wählby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 2002; 4 (E27): 1-12
27. R Development Core Team, R Development Core Team. The comprehensive R archive network [online]. Available from URL: http://cran.r-project.org/ [Accessed 2006 Jan 15]
28. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Contr 1974; 19: 716-23
29. Perri D, Ito S, Rowsell V, et al. The kidney: the body's playground for drugs: an overview of renal drug handling with selected clinical correlates. Can J Clin Pharmacol 2003; 10 (1): 17-23
30. Nierenberg DW. Drug inhibition of penicillin tubular secretion: concordance between in vitro and clinical findings. J Pharmacol Exp Ther 1987; 240 (3): 712-6
31. Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23 (5): 545-51
32. Fujita T, Urban TJ, Leabman MK, et al. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006; 95 (1): 25-36
33. Gaudry SE, Sitar DS, Smyth DD, et al. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin Pharmacol Ther 1993; 54 (1): 23-7
34. Busch AE, Karbach U, Miska D, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 1998; 54 (2): 342-52
35. Fourie J, Escobar MR, Sitar DS. NMDA receptor antagonists to characterize rat renal organic cation transporter function. Eur J Pharmacol 2002; 452 (1): 1-10
36. Launay-Vacher V, Izzedine H, Karie S, et al. Renal tubular drug intransporters. Nephron Physiol 2006; 103 (3): 97-106
37. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 2003; 33 Suppl. 2: 6-9
38. Periclou AP, Ventura D, Sherman T, et al. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004; 38 (9): 1389-94
39. Rao N, Chou T, Ventura D, et al. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Clin Ther 2005; 27 (10): 1596-606
40. Nagy CF, Kumar D, Cullen EI, et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol 2004; 58 Suppl. 1: 18-24
41. Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol 1998; 46 Suppl. 1: 56-60
42. Honegger UE, Quack G, Wiesmann UN. Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and β-adrenergic transmission. Pharmacol Toxicol 1993; 73: 202-8
43. Ishizaki J, Yokogawa K, Ichimura F, et al. Uptake of imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. J Pharmacol Exp Ther 2000; 294 (3): 1088-98
44. Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A 1978; 75 (7): 3327-31